The partnership will concentrate on the development and manufacturing of electric vehicles, enhancing industry capabilities BANGKOK, Oct. 5, 2024 /PRNewswire/ -- UNEX of the Netherlands, a global leader in the research and development of electric vehicles (EVs), and Siam Racing Automobiles (SRA) of Thailand, a world-class automotive design and engineering firm, have announced that their joint venture, SAUNEX, has entered into a strategic cooperation agreement with Saudi Arabia International Industrial Village (SIIVC). The alliance will establish a production facility for EVs in Saudi Arabia, aiming to extend their market reach across the Middle East, North Africa, and Southern Europe. Chatchaval Jiaravanon, a member of the family that controls CP Group, addressed the audience at the signing ceremony. He highlighted the importance of automotive manufacturing as a benchmark of a nation's industrial capabilities. Reflecting on CP Group's past collaboration with China's SAIC to set up a production facility for MG sports cars in Thailand, he noted that the success of automotive ventures relies critically on exemplary technology and leadership. The partnership between SAUNEX and SIIVC is aligned with Saudi Arabia's Vision 2030 strategic initiative, emphasizing sustainable collaboration in the development, production, and marketing of EVs. The goal is to drive significant progress in Saudi Arabia's EV sector and position SAUNEX as a beacon of successful international cooperation between Thailand and Saudi Arabia.Mr. Jiaravanon also remarked that SAUNEX stands at the forefront of electric vehicle R&D, particularly in the application of battery swapping technology and the fields of automotive design and engineering. Their leading model, the Manto, is a luxury electric SUV that utilizes UNEX's battery swapping technology, enhanced by SRA's sophisticated design and engineering. It significantly outperforms competitors, offering a superior choice for future EVs free from the usual range limitations. Top management executives from UNEX at the ceremony pointed out that under the leadership of Dr. Faisal Abdullah, CEO of SIIVC, the project aims to develop cutting-edge automotive production and battery swapping facilities in Saudi Arabia, manufacturing a full line-up of vehicle models including sedans, SUVs, and vans. The partnership also includes collaboration with CP Group and automotive supply chains in Thailand and China, aiming to create a sustainable and advanced industrial ecosystem that sets a global standard for the electric vehicle industry.View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/saunex-partners-with-saudi-siivc-in-strategic-ev-initiative-302268179.html SOURCE UNEX

HANGZHOU, China, Oct. 5, 2024 /PRNewswire/ -- The Global Mayors Dialogue: Hangzhou and the 9th Hangzhou International Sister City Mayors Conference was launched on Sept 25, bringing together mayors and representatives from 24 cities across 15 countries. The key discussions focused on urban governance and sustainable development and the integration of digital and physical spaces, coinciding with the third Global Digital Trade Expo. Hangzhou, home to three UNESCO World Heritage sites West Lake, the Grand Canal (Hangzhou section), and the Liangzhu Archaeological Site, has rapidly expanded its international sister city network. The city boasts a strong cultural heritage, thriving digital economy, and business-friendly environment, connecting it with 31 sister cities and 42 partner cities worldwide. As the host of the event, Hangzhou aims to foster deeper global collaboration and dialogue between global cities. In this video, Venezuelan content creator Rafael Saavedra engages with the Governor of the Region of Western Greece, the Mayor of Kota Kinabalu, and the City Manager of Cape Town. They discuss the challenges their cities face in urban governance, share insights on digitalization, and highlight the conference's significance. Rafael also participates in a tree-planting initiative and visits the Alibaba Xixi Campus and the Liangzhu Archaeological Site, learning about Hangzhou's commitment to digital economic development, cultural preservation, and environmental protection. Curious about how mayors from around the world have evaluated Hangzhou and the exchanges that took place on urban governance? Watch this video to find your answers!View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/china-matters-feature-exploring-new-frontiers-on-urban-governance-302268174.html SOURCE China Matters

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024. Details of Poster Presentations: ATG-201 (CD19 x CD3 T-cell Engager)Title: ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseasesAbstract Number: 1067Poster Abstract Presentation at the SITC Immune Engineering WorkshopDate: November 7, 2024Time: 3:10 PM - 5:00 PM (Central Standard Time)          5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time)Poster Presentation at the SITC 39th Annual MeetingDate: November 8, 2024Time: 9:00 AM - 7:00 PM (Central Standard Time)          11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)  ATG-107 (FLT3 x CD3 T-cell Engager)Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AMLAbstract Number: 1068Poster Abstract Presentation at the SITC Immune Engineering WorkshopDate: November 7, 2024Time: 3:10 PM - 5:00 PM (Central Standard Time)           5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time)Poster Presentation at the SITC 39th Annual MeetingDate: November 9, 2024Time: 9:00 AM - 8:30 PM (Central Standard Time)          11:00 PM, Nov 9 – 10:30 AM, Nov 10, 2024 (Beijing Time) ATG-106 (CDH6 x CD3 T-cell Engager)Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacyAbstract Number: 1069Poster Presentation at the SITC 39th Annual MeetingDate: November 8, 2024Time: 9:00 AM - 7:00 PM (Central Standard Time)          11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)  About the AnTenGager™ Platform The AnTenGager™ Platform is a proprietary "2+1" T cell engager (TCE) platform developed by Antengene.  AnTenGager™ TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager™ TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors. Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/antengene-to-present-results-from-three-programs-at-the-2024-sitc-annual-meeting-302267531.html SOURCE Antengene Corporation Limited

GAIL and AM Green will jointly explore setting up of solar/wind hybrid renewable projects to enable supply of Renewable Energy - Round the Clock (RE-RTC)Partnership to focus on the long-term supply of carbon dioxide (CO2), and eMethanol production and exploration across IndiaAMSTERDAM and NEW DELHI, Oct. 4, 2024 /PRNewswire/ -- GAIL (India) Limited and AM Green B.V. (AMG) have signed a Memorandum of Understanding (MoU) to explore projects aimed at advancing sustainable energy solutions in India. The partnership focuses on the long-term supply of carbon dioxide (CO2) for hybrid renewable energy project, and eMethanol production and exploration across India.Shri Sumit Kishore, Executive Director (Business Development and Exploration & Production), GAIL and Shri Mahesh Kolli, Group President, AM Green signed the MoU in presence of Shri Rajeev Singhal, Director (Business Development), GAIL. In line with the MoU, both the parties envision to jointly explore setting up of solar/wind hybrid renewable projects up to 2.5 GW across India. The hybrid solar/wind projects combined with Greenko's upcoming Pump Storage Projects are poised to supply Round the Clock power to the end users including the proposed eMethanol project. Both the parties envisage to undertake studies for long-term supply of around 350 KTA CO2 generated by GAIL in its gas processing plants to produce eMethanol, an environmentally friendly fuel that can reduce carbon emissions and promote a circular economy. GAIL shall also have an equity option to invest in the proposed eMethanol project, ensuring a strategic partnership that supports both companies' objectives in promoting sustainable energy solutions. Mahesh Kolli, Group President of AM Green: "We are delighted to partner with GAIL on one of the world's largest carbon-free, renewable energy supply contracts. This partnership demonstrates AM Green's emerging leadership position as a global clean energy transition solutions platform while contributing to India's ambition of emerging as an exporter of reliable, sustainable and lowest cost green molecules and its derivatives accelerating industrial decarbonization globally. The production of green methanol shall also help in decarbonization of hard to abate sectors like shipping, steel, cement etc." Rajeev Singhal, Director (Business Development) of GAIL: "The signing of this MoU with AM Green underscores our commitment to pioneering sustainable energy solutions. By facilitating the supply of CO2 for eMethanol production, we are taking a proactive approach to reduce carbon emissions and support alternative fuel development. Development of renewable energy projects will support reducing carbon footprint of the country and advancing India's transition to a greener energy landscape. The partnership between GAIL and AMG is set to augment technological innovation in India while also promoting economic growth and environmental sustainability." AM Green's production of the green ammonia across multiple locations in India will accelerate its target to achieve 5 MTPA of green ammonia capacity by 2030, and its efforts to achieve net zero targets in India as well as in OECD markets. This will be equivalent to about 1 MTPA of green hydrogen, representing a fifth of India's target for green hydrogen production under the country's National Green Hydrogen Mission and 10 per cent of Europe's target for green hydrogen imports by 2030. AM Green will also establish large-scale bio refineries that utilize multiple feedstocks & produce high-value green products enabling global decarbonization in aviation, fuels, chemicals and other industrial sectors. For further enquiries:Jyoti KumarCorporate CommunicationGAIL (India) LimitedT: +91 9818805711E: jyotik@gail.co.in Suheil ImtiazPublic Affairs & Strategic CommunicationsAM GreenM: + 91 94401 59289E: suheil.m@amgreen.com   SOURCE AM Green

HYDERABAD, India, Oct. 4, 2024 /PRNewswire/ -- Cyient DLM, a leading integrated electronics manufacturing company, announced today its acquisition of Altek Electronics, a prominent EMS (Electronic Manufacturing Services) company based in the United States. This strategic move marks a significant milestone in Cyient DLM's growth plan, expanding its presence in the North American market and strengthening its capabilities across key sectors.Altek Electronics, with its strong footprint in the Medical & Healthcare and Industrial sectors, strengthens Cyient DLM's capability in these sectors and adds a diverse customer base to Cyient DLM. The acquisition adds a number of Fortune 500 clients to Cyient DLM's portfolio and strategic engagements with multiple other key clients. Additionally, Altek Electronics, with its ITAR certification, positions Cyient DLM well to address the growing US Defense market. Through this acquisition Cyient DLM will also significantly expand its manufacturing capacity adding additional 80,000 sft of manufacturing area to cater to its clients globally. This acquisition is in line with Cyient DLM's strategic roadmap to expand geographic footprint, add strategic clients and increase client proximity. Krishna Bodanapu, Executive Chairman of Cyient DLM, commented, "This acquisition is a pivotal moment for Cyient DLM. It expands our global footprint, brings us closer to our strategic customers, and significantly strengthens our capabilities. With this acquisition, Cyient DLM is not only broadening its reach into the Medical & Healthcare and Industrial sectors but also bolstering its capabilities for the Defense sector through ITAR compliance. Altek Electronics' proven track record with key industry leading clients will accelerate Cyient DLM's ability to deliver high-performance, reliable services across these sectors. Anthony Montalbano, CEO of Cyient DLM, added, "This acquisition is more than just an expansion, it is an important milestone for Cyient DLM. With the addition of Altek Electronics' expertise, we are enhancing our manufacturing capability & capacity, and strengthening our competitive position in the North American market. This allows us to continue offering world-class services that meet the evolving needs of our customers." David Altschuler, CEO of Altek Electronics, mentioned, "Joining forces with Cyient DLM opens new avenues for us to scale our operations and leverage their global resources and industry expertise. As we enter this new chapter, we remain committed to upholding the values that have defined our success and look forward to leveraging expanded resources and capabilities to better serve our customers, suppliers, and stakeholders." This acquisition highlights Cyient DLM's commitment to expanding its global footprint, diversifying its customer base, and positioning itself as a leader in the EMS sector for highly regulated and safety-critical industries. This move sets the stage for Cyient DLM's next phase of growth, ensuring long-term success and greater value for its customers worldwide. About Cyient DLM Cyient DLM (Estd: 1993, NSE: CYIENTDLM) is a leading Integrated Electronics Manufacturing Solutions provider that offers Design Led Manufacturing (DLM) solutions across the entire product lifecycle. With a focus on safety-critical electronics in highly regulated industries, Cyient DLM delivers design, manufacturing, testing, and certification support to ensure the highest standards of reliability, safety, and performance. The company serves customers in diverse sectors including Aerospace & Défense, Industrial, and Medical & Healthcare, with a commitment to driving innovation and value-driven solutions. About Altek Electronics Altek Electronics, a premier electronics contract manufacturing services provider based in Torrington, Connecticut, has been a trusted partner in the electronics industry for over five decades. Specializing in high-mix, low-to-medium volume PCB assemblies, Altek has built a reputation for delivering exceptional quality, reliability, and customer service. Altek's expertise in engineering support, quick turn prototypes, and full-scale production has enabled the company to serve a diverse range of industries, including Medical, Industrial, Aerospace, and Defense. For more information, please visit www.cyientdlm.com   Gowtham Uyalla Kaizzen PR gowtham.uyalla@kaizzencomm.com     Pooja Jamwal Cyient DLM   pooja.jamwal@cyientdlm.com   Phalguna Hari Jandhyala Cyient  phalguna.harijandhyala@cyient.com     SOURCE Cyient